# A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Source: https://onco.cc/trials/nct03592264/  
OnCo record `nct03592264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AST-3424 run by OBI Pharma, Inc, terminated.

## Summary

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03592264 by OBI Pharma, Inc, with 68 participants enrolled, started 2018-07-02. Conditions recorded: Solid Tumor and Pancreatic Adenocarcinoma. Interventions recorded: OBI-3424.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03592264
- Phase: 1/2
- Setting: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
- Sponsor: OBI Pharma, Inc
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT03592264: https://clinicaltrials.gov/study/NCT03592264

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [AST-3424](https://onco.cc/drugs/ast-3424/)
- companies: [Ascentawits Pharmaceuticals](https://onco.cc/companies/ascentawits-pharmaceuticals/), [OBI Pharma](https://onco.cc/companies/obi-pharma/), [Zhejiang Hisun Pharmaceutical](https://onco.cc/companies/zhejiang-hisun/)

---
JSON: https://onco.cc/api/v1/entities/nct03592264.json